Bayer's Twin Catalysts: Debt Reduction Strategy and Supreme Court Verdict Set the Tone

Bayer's Q1 EBITDA rises 9% to €4.45bn, but free cash flow turns negative €2.3bn on Monsanto settlements. Supreme Court Durnell decision in June could reshape legal risk.

Bayer is walking a tightrope between operational momentum and legal turbulence. The German life sciences group delivered a solid first quarter, yet its stock remains stuck in a narrow range as investors weigh a €2.3 billion cash drain against prospects for a pivotal Supreme Court ruling in late June.

Q1 delivers a profit surge – but cash tells another story

First-quarter earnings before interest, tax, depreciation and amortisation (EBITDA) before special items came in at €4.45 billion, a nine per cent increase year-on-year. Revenue reached €13.4 billion, driven by the Crop Science division, which posted currency-adjusted growth of nearly seven per cent. On a per-share basis, adjusted earnings almost doubled to €2.71 from €1.32 a year earlier.

The cash flow statement, however, laid bare the cost of Bayer’s ongoing legal battles in the US. Free cash flow swung to minus €2.3 billion, crushed by settlement payments tied to legacy litigation from the Monsanto acquisition. That shortfall is the central reason management will face pointed questions at the Deutsche Bank European Champions Conference in Frankfurt on 27 May.

Frankfurt conference: debt reduction in the spotlight

At the conference, Bayer’s leadership is expected to outline how the “Dynamic Shared Ownership” efficiency programme can relieve balance sheet pressure in the near term. Concrete savings targets and a credible timeline will be crucial to convincing investors that the debt trajectory is turning. With liquidity preservation taking priority over shareholder returns, the dividend outlook remains subdued – market estimates currently stand at €0.11 per share for the current financial year.

The stock has recovered strongly from its 52-week low in May 2025, more than doubling since then. But at around €39.20 – just above its 50-day moving average of €38.91 – it still trades roughly 20 per cent below the yearly high of €49.17. Analysts at UBS and DZ Bank reiterated buy recommendations on 19 and 20 May respectively, while Barclays nudged its target price higher after the quarterly numbers. The consensus view is that current levels already discount legal risk but undervalue the potential of the pharmaceutical pipeline.

Eyes on Washington: the Durnell case

The biggest swing factor for Bayer’s medium-term outlook is the US Supreme Court’s upcoming decision in the case known as “Durnell”. The justices heard oral arguments in late April and are expected to rule at the end of June. The core legal question is whether federal Environmental Protection Agency (EPA) approvals preempt local lawsuits – a principle Bayer argues should shield it from thousands of claims alleging inadequate labelling.

To bolster its position, Bayer has joined forces with industry groups in the “Modern Ag Alliance”, pushing for uniform federal labelling standards. Separately, Washington is debating whether to classify domestic glyphosate production as essential infrastructure, a move that could heighten political pressure on the judiciary. A victory in the Supreme Court would remove the legal underpinning of countless pending cases; a defeat would cement the financial overhang.

Pharma pipeline provides a counterpoint

Away from the courtroom, Bayer’s pharmaceutical division is making headway. The US Food and Drug Administration granted accelerated review to Asundexian, the oral Factor XIa inhibitor that the company hopes will become a blockbuster in stroke prevention. In mid-May, the group also presented encouraging Phase II data for Darolutamid (marketed as Nubeqa) in a new cancer indication. These clinical milestones are designed to offset looming patent expiries on older drugs and strengthen the narrative that Bayer’s long-term value extends beyond its legal headaches.

DZ Bank, in a recent note, raised its target price to €51 and upgraded the stock to “Buy”, signalling confidence that the risk/reward balance is shifting. The market will have two more catalysts to watch after the Supreme Court ruling: the Q2 earnings release on 4 August, and any further updates on the debt reduction plan from the Frankfurt conference.